Triptorelin depot stimulation test for central precocious puberty

被引:6
作者
Strich, David [1 ]
Kvatinsky, Noa [2 ]
Hirsch, Harry J. [3 ]
Gillis, David [4 ,5 ]
机构
[1] Clalit Hlth Serv, Pediat Specialists Clin, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel
[3] Shaare Zedek Med Ctr, Dept Pediat, Jerusalem, Israel
[4] Hadasah Hebrew Univ, Med Ctr, Dept Pediat, IL-91120 Jerusalem, Israel
[5] Hadasah Hebrew Univ, Med Ctr, Pediat Endocrinol Unit, IL-91120 Jerusalem, Israel
关键词
central precocious puberty; gonadotropins; triptorelin; HORMONE; LEUPROLIDE; INJECTION; THERAPY; AGONIST; GROWTH; GIRLS;
D O I
10.1515/jpem-2012-0015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Acute gonadotropin responses following depot leuprolide acetate injection are useful for monitoring therapeutic efficacy in central precocious puberty. Similar monitoring of therapy in patients treated with another widely used GnRH agonist, depot triptorelin, has not yet been reported. Objective: The objective of this study was to test the use of gonadotropin levels after therapeutic injections of depot triptorelin for evaluating efficacy of therapy. Patients and methods: Thirty-two patients (29 girls and three boys) were treated with triptorelin depot, 3.75 mg per vial, between 2006 and 2010. Treatment was initiated at 8.27 +/- 1.76 years (range, 4.6-11.6 years). Blood was drawn before and at variable times between 30 min and 2 h after injections. Clinical tests were retrospectively collected. Results: After the first injection, the 60-min mean luteinizing hormone (LH) level was 21.6.1 +/- 18.0 IU/L and the follicle-stimulating hormone (FSH) was 13.5 +/- 3.6 IU/L. After subsequent injections, for those who showed clinical suppression, the standard deviations above the mean were 3.6 IU/L for FSH and 2.1 IU/L for LH. The LH levels of two patients who did not suppress sufficiently were at these limits or higher. Conclusions: Sixty-minute postinjection depot triptorelin levels of LH can be successfully used to evaluate the efficacy of treatment with this agent. Limits for suppressed levels have been determined.
引用
收藏
页码:631 / 634
页数:4
相关论文
共 13 条
  • [1] Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty
    Acharya, Shrikrishna V.
    Gopal, Raju A.
    George, Joe
    Bandgar, Tushar R.
    Menon, Padma S.
    Shah, Nalini S.
    [J]. PITUITARY, 2009, 12 (04) : 335 - 338
  • [2] Serum luteinizing hormone rises within minutes after depot leuprolide injection: Implications for monitoring therapy
    Bhatia, S
    Neely, EK
    Wilson, DM
    [J]. PEDIATRICS, 2002, 109 (02) : E30
  • [3] A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls
    Brito, VN
    Latronico, AC
    Arnhold, IJP
    Mendonca, BB
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (09) : 4338 - 4342
  • [4] Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
    Carel, Jean-Claude
    Eugster, Erica A.
    Rogol, Alan
    Ghizzoni, Lucia
    Palmert, Mark R.
    [J]. PEDIATRICS, 2009, 123 (04) : E752 - E762
  • [5] Happ J, 1987, HORMONAL MANIPULATIO, P249
  • [6] Free α-Subunit Is the Most Sensitive Marker of Gonadotropin Recovery after Treatment of Central Precocious Puberty with the Histrelin Implant
    Hirsch, Harry J.
    Lahlou, Najiba
    Gillis, David
    Strich, David
    Rosenberg-Hagen, Binyamina
    Chertin, Boris
    Farkas, Amicur
    Hartman, Hadassa
    Spitz, Irving M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06) : 2841 - 2844
  • [7] USE OF LEUPROLIDE ACETATE RESPONSE PATTERNS IN THE EARLY DIAGNOSIS OF PUBERTAL DISORDERS - COMPARISON WITH THE GONADOTROPIN-RELEASING-HORMONE TEST
    IBANEZ, L
    POTAU, N
    ZAMPOLLI, M
    VIRDIS, R
    GUSSINYE, M
    CARRASCOSA, A
    SAENGER, P
    VICENSCALVET, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (01) : 30 - 35
  • [8] KULIN HE, 1973, PEDIATRICS, V51, P260
  • [9] Kunz GJ, 2007, J PEDIATR ENDOCR MET, V20, P1189
  • [10] Lahlou N, 2000, J PEDIATR ENDOCR MET, V13, P723